<DOC>
	<DOCNO>NCT00004327</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate efficacy octreotide , somatostatin octapeptide analog , decrease gastrointestinal bleeding patient hormone-refractory hereditary hemorrhagic telangiectasia senile ectasia .</brief_summary>
	<brief_title>Phase II Pilot Study Octreotide , Somatostatin Octapeptide Analog , Gastrointestinal Hemorrhage Hormone-Refractory Hereditary Hemorrhagic Telangiectasia Senile Ectasia</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients treat subcutaneous injection octreotide twice day . The dose adjust base response . If requirement transfusion intravenous iron 4 week hemoglobin great 10 mg/dL , therapy continue 1 year . If decrease bleed 10 week , patient remove study .</detailed_description>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Dilatation , Pathologic</mesh_term>
	<mesh_term>Gastrointestinal Hemorrhage</mesh_term>
	<mesh_term>Telangiectasia , Hereditary Hemorrhagic</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Hereditary hemorrhagic telangiectasia senile ectasia Refractory unable tolerate hormonal therapy , i.e . : Estrogen Progesterone Danazol Gastrointestinal ( GI ) hemorrhage require transfusion within past 3 month Recurrent GI bleed 1 year At least 4 unit pack RBCs transfuse within past year OR intravenous iron require 4 time within past year No likely source hemorrhage determine within past year Prior/Concurrent Therapy Disease hormonerefractory Patient Characteristics No octreotide sensitivity</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2000</verification_date>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>hematologic disorder</keyword>
	<keyword>hereditary hemorrhagic telangiectasia</keyword>
	<keyword>rare disease</keyword>
	<keyword>senile ectasia</keyword>
</DOC>